Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

NCT04663386 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2021-09-23

No results posted yet for this study

Summary

This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.

Conditions

Interventions

DRUG

Budesonide-Formoterol

Dry powder inhaler

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Jorn Ossum · Flattum Legesenter

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2021-09-14
Completion
2021-09-14

Countries

  • Norway

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04663386 on ClinicalTrials.gov